Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Biocon to invest over Rs 1493 crore capex for current fiscal

Ruchika Sharma4 July 2020 1:40 PM IST

The capex will be funded through a combination of contribution from internal accruals, debt raise as well as an additional private equity investment...

Granules Pharma recalls Metformin Hydrochloride Tablets in US over excessive NDMA levels

Ruchika Sharma4 July 2020 1:36 PM IST

Granules' test results showed NDMA levels above the FDA acceptable limit in one (1) out of the twelve (12) batches distributed to the US market. All...

Ensure Availability of Critical Medical Equipment: Health Ministry to NPPA

Ruchika Sharma4 July 2020 10:45 AM IST

A Stakeholders Consultation with Medical Devices Industry Associations and Civil Society Group was held in NPPA on 1st July 2020 wherein it was...

Govt launches 'Drug Discovery Hackathon' to develop anti-COVID drug

Ruchika Sharma4 July 2020 10:30 AM IST

The initiative is being jointly carried out by the 'MHRD's Innovation Cell (MIC)', All India Council for Technical Education (AICTE) and the Council...

Sanofi, Regeneron arthritis drug Kevzara fails COVID-19 study

Ruchika Sharma4 July 2020 10:00 AM IST

Paris: Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the U.S. Phase 3 trial of Kevzara (sarilumab) 400 mg in COVID-19 patients...

CDSCO shows green flag to Mylan for remdesivir for 'restricted emergency use'

Ruchika Sharma3 July 2020 2:22 PM IST

Written informed consent of each patient is required before the use of the drug while active post-marketing surveillance data and reporting of serious...

Zydus Cadila COVID-19 vaccine gets DCGI nod for human clinical trials

Ruchika Sharma3 July 2020 11:08 AM IST

With ZyCoV-D, the Company has successfully established the DNA vaccine platform in the country using non-replicating and a non-integrating plasmid...

Punjab Govt conducts raids to check black marketing of Masks, sanitizers

Ruchika Sharma3 July 2020 10:30 AM IST

Ms Kaur said that they did not find any instance of these essential commodities being sold at an overpriced rate or in black.

COVID ventilators supplied to States, UTs have Bilevel Positive Airway Pressure mode, cost-effective: Centre

Ruchika Sharma3 July 2020 9:45 AM IST

The Ministry comes with the clarification following some media reports that the issue of BiPAP mode not being available in the ventilators supplied by...

Shilpa Medicare launches generic Axitinib to treat advanced kidney cancer

Ruchika Sharma2 July 2020 1:18 PM IST

AXISHIL is used to treat patients suffering from Advanced Renal Cell Carcinoma (RCC).

COVID 19: Dr Reddy's Labs collaborates with FUJIFILM, Global Response Aid for Avigan (favipiravir)

Ruchika Sharma2 July 2020 12:48 PM IST

FUJIFILM will grant Dr.Reddy's right to use Avigan®'s patents of formulation and manufacturing method.

Cadila Pharma launches immunity booster syrup under brand name "Cadimmune"

Ruchika Sharma2 July 2020 12:28 PM IST

The formulation will be available in syrup form, for adults and for paediatric use, and will help in boosting the immunity.

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok